Halia Therapeutics
Halia Therapeutics, Inc. is a privately held clinical-stage biopharmaceutical company headquartered in Lehi, Utah, founded in 2017 and led by CEO Dr. David Bearss. Halia discovers and develops small-molecule therapies that target the immune system's inflammatory response — chiefly allosteric NEK7/NLRP3 inflammasome inhibition and LRRK2 inhibition — to resolve the chronic inflammation that drives hematologic, metabolic and neurodegenerative disease. Its lead clinical program, ofirnoflast (HT-6184), holds FDA Fast Track and Orphan Drug designation for lower-risk myelodysplastic syndromes; HT-4253, an LRRK2 inhibitor aimed at neuroinflammation and Alzheimer's prevention in APOE4 carriers, has completed a first-in-human Phase 1 study. The company also markets a "genetic resilience" research platform (GENMOR) built on family-cohort genomics. Halia is a drug developer, not a software vendor: it publishes a Webflow corporate site with pipeline, platform and press pages, and no developer program, public API, SDK or machine-readable specification of any kind.
Halia Therapeutics is profiled on the APIs.io network. Tagged areas include Company, Biotechnology, Pharmaceuticals, Life Sciences, and Drug Discovery.
Halia Therapeutics’ developer surface includes engineering blog, support, and 4 more developer resources.
Kin Score
Security Posture 1
Authentication, domain security, vulnerability disclosure, and trust-center signals.
Resources
Access & Security 1
Authentication, authorization, and security posture
Operate 1
Status, limits, changes, and where to get help
Commercial 1
Pricing, plans, and the legal terms of use
Company 3
The organization behind the API
Source (apis.yml)
Work with this as data
Every provider here is available over the APIs.io API and to AI agents over MCP.